Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Published byClement Moore Modified over 5 years ago

Similar presentations

Presentation on theme: "Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different."— Presentation transcript:

1 Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different doses in rats. Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different doses in rats. Intraperitoneal NPH insulin and DET produced similar levels as a function of dose in plasma (A and D). Likewise, there were dose-dependent increases of CSF insulin with both NPH insulin and DET, with apparent saturation of the CSF insulin levels occurring by the 3 units/kg dose (B and E). Plasma glucose decreased in a dose-dependent manner after intraperitoneal NPH insulin or DET (C and F). Significant differences are described in the text. Denovan P. Begg et al. Diabetes 2015;64: ©2015 by American Diabetes Association

Download ppt "Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different."

Similar presentations

Independent variables (baseline) Loge (HOMA-IR) b P

Independent variables (baseline) Loge (HOMA-IR) b P
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.

Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Blood glucose, insulin and C-peptide concentrations (A), insulin dose received and BGC (B) for one neonate treated with insulin over 24 hours. Blood glucose,

Blood glucose, insulin and C-peptide concentrations (A), insulin dose received and BGC (B) for one neonate treated with insulin over 24 hours. Blood glucose,
One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.
A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.
(A) Plasma renin activity in Wistar rats, SHRs, and DOCA-salt rats, n = 8 to 9/group; data are presented as mean ± S.E.M. Dose-response relationship on.

(A) Plasma renin activity in Wistar rats, SHRs, and DOCA-salt rats, n = 8 to 9/group; data are presented as mean ± S.E.M. Dose-response relationship on.
Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.
Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.
Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.
Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.
Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.
1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.
Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.
TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Similar presentations

Ads by Google